Cargando…

SARS-CoV-2 Omicron: Light at the End of the Long Pandemic Tunnel or Another False Dawn for Immunodeficient Patients?

COVID-19 has had a disastrous impact on the world. Apart from at least 6 million deaths, countless COVID-19 survivors are suffering long-term physical and psychiatric morbidity. Hundreds of millions have been plunged into poverty caused by economic misery, particularly in developing nations. Early i...

Descripción completa

Detalles Bibliográficos
Autores principales: Ameratunga, Rohan, Leung, Euphemia, Woon, See-Tarn, Chan, Lydia, Steele, Richard, Lehnert, Klaus, Longhurst, Hilary
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Academy of Allergy, Asthma & Immunology 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9220855/
https://www.ncbi.nlm.nih.gov/pubmed/35752434
http://dx.doi.org/10.1016/j.jaip.2022.06.011
_version_ 1784732476005941248
author Ameratunga, Rohan
Leung, Euphemia
Woon, See-Tarn
Chan, Lydia
Steele, Richard
Lehnert, Klaus
Longhurst, Hilary
author_facet Ameratunga, Rohan
Leung, Euphemia
Woon, See-Tarn
Chan, Lydia
Steele, Richard
Lehnert, Klaus
Longhurst, Hilary
author_sort Ameratunga, Rohan
collection PubMed
description COVID-19 has had a disastrous impact on the world. Apart from at least 6 million deaths, countless COVID-19 survivors are suffering long-term physical and psychiatric morbidity. Hundreds of millions have been plunged into poverty caused by economic misery, particularly in developing nations. Early in the pandemic, it became apparent certain groups of individuals such as the elderly and those with comorbidities were more likely to suffer severe disease. In addition, patients with some forms of immunodeficiency, including those with T-cell and innate immune defects, were at risk of poor outcomes. Patients with immunodeficiencies are also disadvantaged as they may not respond optimally to COVID-19 vaccines and often have pre-existing lung damage. SARS-CoV-2 Omicron (B.1.529) and its subvariants (BA.1, BA.2, etc) have emerged recently and are dominating COVID-19 infections globally. Omicron is associated with a reduced risk of hospitalization and appears to have a lower case fatality rate compared with previous SARS-CoV-2 variants. Omicron has offered hope the pandemic may finally be coming to an end, particularly for vaccinated, healthy individuals. The situation is less clear for individuals with vulnerabilities, particularly immunodeficient patients. This perspective offers insight into potential implications of the SARS-CoV-2 Omicron variant for patients with immunodeficiencies.
format Online
Article
Text
id pubmed-9220855
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher American Academy of Allergy, Asthma & Immunology
record_format MEDLINE/PubMed
spelling pubmed-92208552022-06-24 SARS-CoV-2 Omicron: Light at the End of the Long Pandemic Tunnel or Another False Dawn for Immunodeficient Patients? Ameratunga, Rohan Leung, Euphemia Woon, See-Tarn Chan, Lydia Steele, Richard Lehnert, Klaus Longhurst, Hilary J Allergy Clin Immunol Pract Review and Feature Article COVID-19 has had a disastrous impact on the world. Apart from at least 6 million deaths, countless COVID-19 survivors are suffering long-term physical and psychiatric morbidity. Hundreds of millions have been plunged into poverty caused by economic misery, particularly in developing nations. Early in the pandemic, it became apparent certain groups of individuals such as the elderly and those with comorbidities were more likely to suffer severe disease. In addition, patients with some forms of immunodeficiency, including those with T-cell and innate immune defects, were at risk of poor outcomes. Patients with immunodeficiencies are also disadvantaged as they may not respond optimally to COVID-19 vaccines and often have pre-existing lung damage. SARS-CoV-2 Omicron (B.1.529) and its subvariants (BA.1, BA.2, etc) have emerged recently and are dominating COVID-19 infections globally. Omicron is associated with a reduced risk of hospitalization and appears to have a lower case fatality rate compared with previous SARS-CoV-2 variants. Omicron has offered hope the pandemic may finally be coming to an end, particularly for vaccinated, healthy individuals. The situation is less clear for individuals with vulnerabilities, particularly immunodeficient patients. This perspective offers insight into potential implications of the SARS-CoV-2 Omicron variant for patients with immunodeficiencies. American Academy of Allergy, Asthma & Immunology 2022-09 2022-06-22 /pmc/articles/PMC9220855/ /pubmed/35752434 http://dx.doi.org/10.1016/j.jaip.2022.06.011 Text en © 2022 American Academy of Allergy, Asthma & Immunology. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Review and Feature Article
Ameratunga, Rohan
Leung, Euphemia
Woon, See-Tarn
Chan, Lydia
Steele, Richard
Lehnert, Klaus
Longhurst, Hilary
SARS-CoV-2 Omicron: Light at the End of the Long Pandemic Tunnel or Another False Dawn for Immunodeficient Patients?
title SARS-CoV-2 Omicron: Light at the End of the Long Pandemic Tunnel or Another False Dawn for Immunodeficient Patients?
title_full SARS-CoV-2 Omicron: Light at the End of the Long Pandemic Tunnel or Another False Dawn for Immunodeficient Patients?
title_fullStr SARS-CoV-2 Omicron: Light at the End of the Long Pandemic Tunnel or Another False Dawn for Immunodeficient Patients?
title_full_unstemmed SARS-CoV-2 Omicron: Light at the End of the Long Pandemic Tunnel or Another False Dawn for Immunodeficient Patients?
title_short SARS-CoV-2 Omicron: Light at the End of the Long Pandemic Tunnel or Another False Dawn for Immunodeficient Patients?
title_sort sars-cov-2 omicron: light at the end of the long pandemic tunnel or another false dawn for immunodeficient patients?
topic Review and Feature Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9220855/
https://www.ncbi.nlm.nih.gov/pubmed/35752434
http://dx.doi.org/10.1016/j.jaip.2022.06.011
work_keys_str_mv AT ameratungarohan sarscov2omicronlightattheendofthelongpandemictunneloranotherfalsedawnforimmunodeficientpatients
AT leungeuphemia sarscov2omicronlightattheendofthelongpandemictunneloranotherfalsedawnforimmunodeficientpatients
AT woonseetarn sarscov2omicronlightattheendofthelongpandemictunneloranotherfalsedawnforimmunodeficientpatients
AT chanlydia sarscov2omicronlightattheendofthelongpandemictunneloranotherfalsedawnforimmunodeficientpatients
AT steelerichard sarscov2omicronlightattheendofthelongpandemictunneloranotherfalsedawnforimmunodeficientpatients
AT lehnertklaus sarscov2omicronlightattheendofthelongpandemictunneloranotherfalsedawnforimmunodeficientpatients
AT longhursthilary sarscov2omicronlightattheendofthelongpandemictunneloranotherfalsedawnforimmunodeficientpatients